Medicine and Dentistry
Patient
100%
Clopidogrel
61%
Thrombotic Thrombocytopenic Purpura
33%
Ticlopidine
22%
Therapeutic Procedure
16%
Plasma Exchange
11%
Adverse Event
5%
Surveillance
5%
Combination Therapy
5%
Diagnosis
5%
Cohort Analysis
5%
Antiplatelet Drug
5%
Thienopyridine
5%
Association
5%
Incidence
5%
Mechanism of Action
5%
Relapse
5%
Nursing and Health Professions
Clopidogrel
61%
Thrombotic Thrombocytopenic Purpura
33%
Ticlopidine
22%
Plasma Exchange
11%
Adverse Event
5%
Clinical Practice
5%
Physician
5%
Cohort Analysis
5%
Combination Therapy
5%
Diagnosis
5%
Antithrombocytic Agent
5%
Blood Bank
5%
Hematologist
5%
Laboratory
5%
Incidence
5%
Procedures
5%
Syndrome
5%
Relapse
5%
Thienopyridine Derivative
5%
Pharmacology, Toxicology and Pharmaceutical Science
Clopidogrel
61%
Thrombotic Thrombocytopenic Purpura
33%
Ticlopidine
22%
Clinical Trial
16%
Adverse Event
5%
Antithrombocytic Agent
5%
Thienopyridine
5%
Incidence
5%
Syndrome
5%
Relapse
5%
Biochemistry, Genetics and Molecular Biology
Clopidogrel
61%
Thrombotic Thrombocytopenic Purpura
33%
Ticlopidine
22%
Chemical Structure
5%
Thienopyridine
5%
Incidence
5%
Association
5%
Cohort Study
5%
Relapse
5%
INIS
patients
50%
purpura
33%
plasma
11%
laboratories
5%
drugs
5%
clinical trials
5%
therapy
5%
banks
5%
blood
5%
surveillance
5%
manufacturers
5%